Evidence mapPaperPMID 34925697Full record

Trial reportOxidative medicine and cellular longevity2021

The Role of RIPC in Preventing Organ Damage, Inflammation, and Oxidative Stress during Lower Limb DSA: A Randomised Controlled Trial.

Karl Kuusik, Teele Kasepalu, Mihkel Zilmer, Jaan Eha, Mare Vähi, Liisi Anette Torop, Jüri Lieberg, Jaak Kals

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Karl KuusikDepartment of Cardiology, Institute of Clinical Medicine, University of Tartu, Puusepa 8, Tartu 50406, Estonia.ORCID https://orcid.org/0000-0001-6035-5901
Teele KasepaluHeart Clinic, Tartu University Hospital, Puusepa 8, Tartu 50406, Estonia.ORCID https://orcid.org/0000-0001-5367-6299
Mihkel ZilmerDepartment of Biochemistry, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Genomics and Translational Medicine, University of Tartu, Puusepa 8, Tartu 50406, Estonia.
Jaan EhaDepartment of Cardiology, Institute of Clinical Medicine, University of Tartu, Puusepa 8, Tartu 50406, Estonia.
Mare VähiInstitute of Mathematics and Statistics, University of Tartu, J. Liivi 2, Tartu 50409, Estonia.
Liisi Anette ToropPathology Service, Tartu University Hospital, Puusepa 8, Tartu 50406, Estonia.
Jüri LiebergDepartment of Vascular Surgery, Surgery Clinic, Tartu University Hospital, Puusepa 8, Tartu 50406, Estonia.
Jaak KalsDepartment of Biochemistry, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Genomics and Translational Medicine, University of Tartu, Puusepa 8, Tartu 50406, Estonia.ORCID https://orcid.org/0000-0002-8745-718X
Tartu University Hospital · EECzech Academy of Sciences, Institute of Mathematics · CZUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDiagnostic digital subtraction angiography (DSA) and DSA with percutaneous transluminal angioplasty (DSA-PTA) are common procedures for diagnosing and treating symptomatic lower extremity arterial disease (LEAD). However, organ damage following DSA and DSA-PTA is often underrecognised and hence undiagnosed. To reduce the risk induced by invasive procedures in symptomatic LEAD patients, the method of remote ischemic preconditioning (RIPC) has been suggested. The aim of the current study was to assess the effect of RIPC intervention on the organ damage markers profile, oxidative stress, and inflammation biomarkers in LEAD patients undergoing DSA and DSA-PTA procedure.

methodsThe RIPC intervention was performed by inflating a standard blood pressure cuff on the patient's upper arm to 200 mmHg for 5 minutes four times with 5-minute perfusion between each cycle. The sham intervention was performed similarly, but the cuff was inflated to 20 mmHg. Changes in the cardiac and renal damage biomarkers' profile, oxidative stress, and inflammation biomarkers were recorded before and 24 hours after DSA or DSA-PTA.

resultsA total of 111 (RIPC 54, sham 57) patients with symptomatic LEAD scheduled for endovascular procedure were randomised, and 102 patients (RIPC 47, sham 55) completed the study protocol. RIPC significantly limited the increase of adiponectine levels after DSA and DSA-PTA, compared to sham intervention (

conclusionIn this controlled clinical study, RIPC failed to improve the profile of renal and cardiac biomarkers in patients with LEAD periprocedurally. RIPC significantly limits the rise in adiponectin levels and may influence the decrease of CK-MB levels 24 hours after endovascular procedure.

Indexed as

Oxidative StressAgedAngiography, Digital SubtractionCase-Control StudiesDouble-Blind MethodFemaleHumansInflammationIschemic PreconditioningLower ExtremityMaleMultiple Organ FailurePeripheral Arterial Disease

Identifiers

PMID34925697
PMCPMC8674049
OpenAlexW4200404259

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.